论文部分内容阅读
至上世纪90年代末,症状缓解仍是炎症性肠病(IBD)疗效评估的重要指标。近年,黏膜愈合(MH)逐渐被纳入IBD的疗效评估,并作为临床试验的重要终点和治疗目标。MH可改变IBD的自然病程,以达持续临床缓解,由此降低患者的住院率和手术风险。本文就MH在IBD临床应用中的价值作一综述。
To the late 90s of last century, symptom relief is still an important indicator of the evaluation of the efficacy of inflammatory bowel disease (IBD). In recent years, mucosal healing (MH) has gradually been incorporated into the efficacy evaluation of IBD and serves as an important endpoint and target of clinical trials. MH can change the natural history of IBD in order to achieve sustained clinical remission, thereby reducing the patient’s hospitalization rate and surgical risk. This article reviews the value of MH in the clinical application of IBD.